News

Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
Zacks Investment Research on MSN1d
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...
Should You Invest $1,000 in Eli Lilly today?
Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...
What Is BMI: Body Mass Index Explained
Body mass index (BMI) has long been a common tool for estimating a person's relative weight status based on a simple height to weight ratio. It's easy to calculate, widely accessible and often used ...
Ozempic vs. Zepbound: Which Is Better For Weight Loss?
A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...
Tell us: How are you planning to afford GLP-1 drugs?
Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...
New Research Reveals Most Effective Obesity Drug: It’s Not Ozempic or Wegovy
A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...